145 related articles for article (PubMed ID: 26459608)
1. DEK: A novel early screening and prognostic marker for breast cancer.
Ying G; Wu Y
Mol Med Rep; 2015 Nov; 12(5):7491-5. PubMed ID: 26459608
[TBL] [Abstract][Full Text] [Related]
2. DEK protein overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma.
Sun J; Bi F; Yang Y; Zhang Y; Jin A; Li J; Lin Z
Oncol Rep; 2017 Feb; 37(2):857-864. PubMed ID: 27959420
[TBL] [Abstract][Full Text] [Related]
3. Significance of DEK overexpression for the prognostic evaluation of non-small cell lung carcinoma.
Liu X; Qi D; Qi J; Mao Z; Li X; Zhang J; Li J; Gao W
Oncol Rep; 2016 Jan; 35(1):155-62. PubMed ID: 26530274
[TBL] [Abstract][Full Text] [Related]
4. DEK overexpression is correlated with the clinical features of breast cancer.
Liu S; Wang X; Sun F; Kong J; Li Z; Lin Z
Pathol Int; 2012 Mar; 62(3):176-81. PubMed ID: 22360505
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of DEK gene is correlated with poor prognosis in hepatocellular carcinoma.
Yi HC; Liu YL; You P; Pan JS; Zhou JY; Liu ZJ; Zhang ZY
Mol Med Rep; 2015 Feb; 11(2):1318-23. PubMed ID: 25351213
[TBL] [Abstract][Full Text] [Related]
6. High expression of DEK is associated with poor prognosis in hepatocellular carcinoma.
Lee SY; Jung W; Lee J; Kim A; Kim HK; Kim BH
Histol Histopathol; 2019 Nov; 34(11):1279-1288. PubMed ID: 31066459
[TBL] [Abstract][Full Text] [Related]
7. DEK over expression as an independent biomarker for poor prognosis in colorectal cancer.
Lin L; Piao J; Gao W; Piao Y; Jin G; Ma Y; Li J; Lin Z
BMC Cancer; 2013 Jul; 13():366. PubMed ID: 23902796
[TBL] [Abstract][Full Text] [Related]
8. High expression of oncoprotein DEK predicts poor prognosis of small cell lung cancer.
Wang X; Lin L; Ren X; Lin Z; Li Z; Li C; Jin T
Int J Clin Exp Pathol; 2014; 7(8):5016-23. PubMed ID: 25197373
[TBL] [Abstract][Full Text] [Related]
9. Low expression of ULK1 is associated with operable breast cancer progression and is an adverse prognostic marker of survival for patients.
Tang J; Deng R; Luo RZ; Shen GP; Cai MY; Du ZM; Jiang S; Yang MT; Fu JH; Zhu XF
Breast Cancer Res Treat; 2012 Jul; 134(2):549-60. PubMed ID: 22585231
[TBL] [Abstract][Full Text] [Related]
10. Expression of MAC30 protein is related to survival and clinicopathological variables in breast cancer.
Xiao M; Li H; Yang S; Huang Y; Jia S; Wang H; Wang J; Li Z
J Surg Oncol; 2013 Apr; 107(5):456-62. PubMed ID: 22996179
[TBL] [Abstract][Full Text] [Related]
11. Increased levels of LAPTM4B, VEGF and survivin are correlated with tumor progression and poor prognosis in breast cancer patients.
Li S; Wang L; Meng Y; Chang Y; Xu J; Zhang Q
Oncotarget; 2017 Jun; 8(25):41282-41293. PubMed ID: 28476037
[TBL] [Abstract][Full Text] [Related]
12. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
[TBL] [Abstract][Full Text] [Related]
13. DEK oncogene is overexpressed during melanoma progression.
Riveiro-Falkenbach E; Ruano Y; García-Martín RM; Lora D; Cifdaloz M; Acquadro F; Ballestín C; Ortiz-Romero PL; Soengas MS; Rodríguez-Peralto JL
Pigment Cell Melanoma Res; 2017 Mar; 30(2):194-202. PubMed ID: 27893188
[TBL] [Abstract][Full Text] [Related]
14. Oncoprotein DEK as a tissue and urinary biomarker for bladder cancer.
Datta A; Adelson ME; Mogilevkin Y; Mordechai E; Sidi AA; Trama JP
BMC Cancer; 2011 Jun; 11():234. PubMed ID: 21663673
[TBL] [Abstract][Full Text] [Related]
15. The unique DEK oncoprotein in women's health: A potential novel biomarker.
de Albuquerque Oliveira AC; Kappes F; Martins DBG; de Lima Filho JL
Biomed Pharmacother; 2018 Oct; 106():142-148. PubMed ID: 29957464
[TBL] [Abstract][Full Text] [Related]
16. High GINS2 transcript level predicts poor prognosis and correlates with high histological grade and endocrine therapy resistance through mammary cancer stem cells in breast cancer patients.
Zheng M; Zhou Y; Yang X; Tang J; Wei D; Zhang Y; Jiang JL; Chen ZN; Zhu P
Breast Cancer Res Treat; 2014 Nov; 148(2):423-36. PubMed ID: 25348432
[TBL] [Abstract][Full Text] [Related]
17. Elevated Aurora B expression contributes to chemoresistance and poor prognosis in breast cancer.
Zhang Y; Jiang C; Li H; Lv F; Li X; Qian X; Fu L; Xu B; Guo X
Int J Clin Exp Pathol; 2015; 8(1):751-7. PubMed ID: 25755770
[TBL] [Abstract][Full Text] [Related]
18. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
[TBL] [Abstract][Full Text] [Related]
19. HDAC2 overexpression is a poor prognostic factor of breast cancer patients with increased multidrug resistance-associated protein expression who received anthracyclines therapy.
Zhao H; Yu Z; Zhao L; He M; Ren J; Wu H; Chen Q; Yao W; Wei M
Jpn J Clin Oncol; 2016 Oct; 46(10):893-902. PubMed ID: 27432453
[TBL] [Abstract][Full Text] [Related]
20. Decreased expression of microRNA-124 is an independent unfavorable prognostic factor for patients with breast cancer.
Dong LL; Chen LM; Wang WM; Zhang LM
Diagn Pathol; 2015 Apr; 10():45. PubMed ID: 25924779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
